IGC Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2015
Filed with the SEC on Aug 14, 2015 and accepted by EDGAR at Aug 14, 2015, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-04-01 to 2015-06-30 | $1.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2015-04-01 to 2015-06-30 | $1.7m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2015-04-01 to 2015-06-30 | $305.4k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2015-04-01 to 2015-06-30 | −$257.3k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-04-01 to 2015-06-30 | $61.9k | us-gaap:InterestExpense |
| Income tax | 3 months2015-04-01 to 2015-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-04-01 to 2015-06-30 | −$382.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-04-01 to 2015-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-04-01 to 2015-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-04-01 to 2015-06-30 | 14,832,065 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2015-04-01 to 2015-06-30 | −$548.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2015-04-01 to 2015-06-30 | $562 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-06-30 | $659.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-06-30 | $4.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-06-30 | $20.6m | us-gaap:Assets |
| Current liabilities | At period end2015-06-30 | $2.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-06-30 | $6.1m | us-gaap:Liabilities |
| Long-term debt | At period end2015-06-30 | $308.2k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2015-06-30 | $1.3m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2015-06-30 | $14.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001185185-15-002205. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.